Efficacy of induction therapy and its impact on the development of delayed graft function in kidney transplant recipients: a single-center retrospective analysis

Davut Akın; Onur Birsen; Ergun Mete; Mevlüt Çeri; Utku Ozgen; Murat Özban

Makale detayları

Efficacy of induction therapy and its impact on the development of delayed graft function in kidney transplant recipients: a single-center retrospective analysis

Yazarlar:

Davut Akın | Onur Birsen | Ergun Mete | Mevlüt Çeri | Utku Ozgen | Murat Özban

Yayıncı:

Pamukkale University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 2, pp.446-452

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001322762

pISSN:

1308-0865

Anahtar kelimeler:

Özet:

 Purpose: This study aimed to evaluate the impact of two different induction therapies-Basiliximab and ATG-Fresenius ATG-F-on early outcomes and the development of delayed graft function DGF in kidney transplant recipients from living or deceased donors at a single center. Matherials and methods: A total of 33 patients over 18 years old who underwent kidney transplantation at a single center between February 2022 and February 2025 were analyzed. Body mass index BMI, demographic data, transplant characteristics, and complications were recorded. DGF was defined as requiring dialysis within the first seven postoperative days. Statistical analyses were performed using the t-test or Mann-Whitney U test for continuous variables and the Chi-square test for categorical variables, with p0.05 considered significant. Results: The mean age of recipients was 39.811.9 years; there were 10 females and 23 males. The mean BMI was 24.53 kgm². Sixteen patients 1416 Basiliximab received living-donor kidneys, while 17 1717 ATG-F received deceased-donor kidneys. Cold ischemia time was 1.10.2 hours for living-donor grafts versus 11.62.0 hours for deceased donors p0.001. Similarly, Pre-transplant dialysis duration was significantly longer in deceased-donor recipients 2.52.6 vs. 9.44.8 years, p0.001. Overall, 30.3 1033 of patients developed DGF, predominantly in those with longer ischemia and dialysis times. Conclusion: In deceased-donor kidney transplant recipients, prolonged cold ischemia and pre-transplant dialysis duration increase the incidence of DGF. The use of ATG-F in patients with high immunologic risk appears to be beneficial and is consistent with the existing literature. However, the limited sample size makes it difficult to clarify the impact of induction therapy on DGF; therefore, larger prospective studies are needed.

 Purpose: This study aimed to evaluate the impact of two different induction therapies-Basiliximab and ATG-Fresenius ATG-F-on early outcomes and the development of delayed graft function DGF in kidney transplant recipients from living or deceased donors at a single center. Matherials and methods: A total of 33 patients over 18 years old who underwent kidney transplantation at a single center between February 2022 and February 2025 were analyzed. Body mass index BMI, demographic data, transplant characteristics, and complications were recorded. DGF was defined as requiring dialysis within the first seven postoperative days. Statistical analyses were performed using the t-test or Mann-Whitney U test for continuous variables and the Chi-square test for categorical variables, with p0.05 considered significant. Results: The mean age of recipients was 39.811.9 years; there were 10 females and 23 males. The mean BMI was 24.53 kgm². Sixteen patients 1416 Basiliximab received living-donor kidneys, while 17 1717 ATG-F received deceased-donor kidneys. Cold ischemia time was 1.10.2 hours for living-donor grafts versus 11.62.0 hours for deceased donors p0.001. Similarly, Pre-transplant dialysis duration was significantly longer in deceased-donor recipients 2.52.6 vs. 9.44.8 years, p0.001. Overall, 30.3 1033 of patients developed DGF, predominantly in those with longer ischemia and dialysis times. Conclusion: In deceased-donor kidney transplant recipients, prolonged cold ischemia and pre-transplant dialysis duration increase the incidence of DGF. The use of ATG-F in patients with high immunologic risk appears to be beneficial and is consistent with the existing literature. However, the limited sample size makes it difficult to clarify the impact of induction therapy on DGF; therefore, larger prospective studies are needed.

 Purpose: This study aimed to evaluate the impact of two different induction therapies-Basiliximab and ATG-Fresenius ATG-F-on early outcomes and the development of delayed graft function DGF in kidney transplant recipients from living or deceased donors at a single center. Matherials and methods: A total of 33 patients over 18 years old who underwent kidney transplantation at a single center between February 2022 and February 2025 were analyzed. Body mass index BMI, demographic data, transplant characteristics, and complications were recorded. DGF was defined as requiring dialysis within the first seven postoperative days. Statistical analyses were performed using the t-test or Mann-Whitney U test for continuous variables and the Chi-square test for categorical variables, with p0.05 considered significant. Results: The mean age of recipients was 39.811.9 years; there were 10 females and 23 males. The mean BMI was 24.53 kgm². Sixteen patients 1416 Basiliximab received living-donor kidneys, while 17 1717 ATG-F received deceased-donor kidneys. Cold ischemia time was 1.10.2 hours for living-donor grafts versus 11.62.0 hours for deceased donors p0.001. Similarly, Pre-transplant dialysis duration was significantly longer in deceased-donor recipients 2.52.6 vs. 9.44.8 years, p0.001. Overall, 30.3 1033 of patients developed DGF, predominantly in those with longer ischemia and dialysis times. Conclusion: In deceased-donor kidney transplant recipients, prolonged cold ischemia and pre-transplant dialysis duration increase the incidence of DGF. The use of ATG-F in patients with high immunologic risk appears to be beneficial and is consistent with the existing literature. However, the limited sample size makes it difficult to clarify the impact of induction therapy on DGF; therefore, larger prospective studies are needed.

 Amaç: Bu çalışma, tek merkezde canlı veya kadavradan böbrek nakli yapılan hastalarda iki farklı indüksiyon tedavisinin-Basiliksimab ve ATG-Fresenius ATG-F-erken dönem sonuçları ve gecikmiş greft fonksiyonu DGF gelişimi üzerindeki etkilerini değerlendirmeyi amaçlamaktadır. Gereç ve yöntem: Şubat 2022 ile Şubat 2025 tarihleri arasında, tek bir merkezde böbrek nakli yapılan 18 yaş üzeri toplam 33 hasta retrospektif olarak incelendi. Vücut kitle indeksi VKİ, demografik veriler, nakil özellikleri ve komplikasyonlar kaydedildi. DGF, transplantasyonu takiben ilk yedi gün içinde diyalize ihtiyaç duyulması şeklinde tanımlandı. Sürekli değişkenler için normal dağılıma göre t-testi veya Mann-Whitney U testi, kategorik değişkenler için ise Ki-kare testi kullanıldı. p0,05 istatistiksel olarak anlamlı kabul edildi. Bulgular: Hastaların yaş ortalaması 39,811,9 yıl olup; 10u kadın, 23ü erkekti. Ortalama VKİ 24,53 kgm² idi. Canlı verici grubundaki 16 hastanın 14üne Basiliksimab, kadaverik gruptaki 17 hastanın tamamına ATG-F uygulanmıştır. Soğuk iskemi süresi, canlı vericili greftlerde 1,10,2 saat; kadavradan alınan greftlerde ise 11,62,0 saat olarak bulunmuştur p0,001. Benzer şekilde, transplantasyon öncesi diyaliz süresi de kadavra verici alıcılarında anlamlı derecede daha uzundu 2,52,6 yıla karşı 9,44,8 yıl; p0,001. Genel olarak hastaların 30,3ünde 1033 DGF gelişmiş olup, bu hastalarda iskemi ve diyaliz süreleri anlamlı derecede daha uzundu. Sonuç: Kadavradan böbrek nakli yapılan hastalarda uzamış soğuk iskemi ve transplantasyon öncesi diyaliz süresi, DGF gelişme insidansını artırmaktadır. Yüksek immünolojik riske sahip hastalarda ATG-F kullanımının faydalı olabileceği mevcut literatür ile uyumludur. Ancak, sınırlı hasta sayısı, indüksiyon tedavisinin DGF üzerindeki etkisini netleştirmeyi güçleştirmektedir; bu nedenle daha geniş prospektif çalışmalara ihtiyaç vardır.

Makale detayları

Efficacy of induction therapy and its impact on the development of delayed graft function in kidney transplant recipients: a single-center retrospective analysis

Yazarlar:

Davut Akın | Onur Birsen | Ergun Mete | Mevlüt Çeri | Utku Ozgen | Murat Özban

Yayıncı:

Pamukkale University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 2, pp.446-452

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001322762

pISSN:

1308-0865

Kidney transplant

end-stage renal disease

hemodialysisBöbrek nakli

son dönem böbrek hastalığı

hemodiyaliz

Sayı

Makale detayları

Efficacy of induction therapy and its impact on the development of delayed graft function in kidney transplant recipients: a single-center retrospective analysis

Yazarlar: Davut Akın | Onur Birsen | Ergun Mete | Mevlüt Çeri | Utku Ozgen | Murat Özban

Yayıncı: Pamukkale University

Ana Başlıklar: İç Hastalıkları

Dergi: Pamukkale Tıp Dergisi Vol.18 Issue 2, pp.446-452

Belge Tipi: Makale

Yayın Tarihi: 1/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001322762

pISSN: 1308-0865

Kidney transplant

end-stage renal disease

hemodialysisBöbrek nakli

son dönem böbrek hastalığı

hemodiyaliz

Sayı

Yazarlar:

Davut Akın | Onur Birsen | Ergun Mete | Mevlüt Çeri | Utku Ozgen | Murat Özban

Yayıncı:

Pamukkale University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 2, pp.446-452

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001322762

pISSN:

1308-0865